尤其在生物医药产业布局上，逢时科技契合了行业发展机遇。发展海洋经济、保护海洋生态环境、加快建设海洋强国，是推动中国式现代化的有机组成和重 要任务。中央财经委员会第六次会议强调，要围绕新制造、新服务、新业态、新模式，加快推动传统海洋产业升级和战略性新兴产业发展，在海洋新能源、 海洋新材料、海洋生物医药及制品等新制造领域取得突破。我国"十五五"规划建议更明确提出，推动海洋经济高质量发展，加快建设海洋强国，加强海洋科 技创新，壮大海洋新兴产业。 高科技含量、高附加值的海洋生物医药产业是我国新兴产业的重要代表，也为破解陆地资源约束、实现产业升级提供了重要路径。在此背景下，逢时科技布 局生物医药产业，契合了时代发展节拍与行业趋势。 从2018年成立至今，这家以南极磷虾开发为核心的企业仅用7年，便完成"专精特新中小企业—山东省瞪羚企业—国家级小巨人"的"三级跳"，不仅低于入 选"小巨人"企业的平均成立年限，也成为所在海洋新兴产业快速发展的典型案例。 運 创 新 致 远 选对赛道，契合发展趋势 年轻的逢时科技之所以能在7年时间内实现跨越式发展，关键在于选对了发展方向。依托对南极磷虾的深度开发与高值化利用，逢时科技布局了海洋 ...

Core Insights - The company Tongshi Technology has been ranked 439th in the "Asia Brand 500" list for 2025, marking a rise of 17 positions from the previous year, and is the only brand in the marine pharmaceuticals and bioproducts sector to be included [1] - Tongshi Technology has maintained its position as the global leader in krill oil sales for two consecutive years, with its VIK brand also being the top-selling domestic brand in China for the same period [3] - The company has made significant investments in research and development, holding 49 intellectual property rights and participating in the formulation of 3 national standards and 9 group standards [4] Product Development and Market Expansion - Tongshi Technology has launched the world's first PQQ small molecule krill peptide, which has generated significant consumer interest [4] - The flagship product, Tongshi VIK blue hat krill oil, is the only domestic product certified for both "maintaining healthy blood lipid levels" and "enhancing immunity," and is now available in 57 Sam's Club locations nationwide [4] - The company's products have been exported to 22 countries and regions, including the UK, France, Germany, and New Zealand, enhancing its global influence [6] Consumer Trust and Quality Assurance - The company has achieved a 40% repurchase rate for its krill oil products, reflecting strong consumer loyalty and trust [6] - Tongshi Technology has established a state-of-the-art transparent production facility in Qingdao, featuring a fully automated production line and stringent quality control measures [6] - The company has successfully produced krill oil with a phospholipid content of 56% and a leak rate controlled to below 0.01%, ensuring consistent quality [6] Strategic Collaborations and Future Plans - The company has initiated strategic collaborations with global leaders in the krill industry and has received patent acceptance for new phospholipid-modified drugs aimed at anti-inflammatory and anti-tumor applications [7] - Tongshi Technology aims to strengthen innovation-driven development and deepen industry-academia-research cooperation to lead breakthroughs in marine pharmaceuticals and bioproducts [9]

Core Insights - The report from the World Brand Lab ranks Fengshi Technology at 439th in the "Asia Brand 500" list for 2025, marking a rise of 17 positions from the previous year, and it is the only brand in the marine pharmaceuticals and bioproducts sector to be included [1] - Fengshi Technology has maintained its position as the global leader in krill oil sales for two consecutive years, with its VIK brand being the top-selling domestic krill oil brand in China [1][2] - The company has made significant investments in R&D, holding 49 intellectual property rights and participating in the formulation of 3 national standards and 9 group standards [1] Product Innovations - In May, Fengshi Technology launched the world's first PQQ small molecule krill peptide, which generated significant consumer interest [2] - The VIK blue hat krill oil product, which is the only domestic krill oil with dual functions of maintaining blood lipid levels and enhancing immunity, was launched in 57 Sam's Club stores nationwide [2] - The company's products are now available in 22 countries and regions, including the UK, France, Germany, and New Zealand [2] Quality and Certifications - Fengshi Technology has achieved a marine phospholipid content of 56% in its krill oil, with a leak rate controlled to below 0.01%, ensuring 100% stable quality [2] - The company has received a 100% compliance certification from the international authority ORIVO for five consecutive years, becoming the first company to achieve ORIVO's "5-year zero defect" quality gold standard certification [2] Strategic Collaborations - The company has initiated a strategic partnership with Norway's Aker to develop a lipid-lowering drug, CaPre, and has collaborated with China Pharmaceutical University on research related to marine peptides for anti-tumor and anti-aging applications [3] - Fengshi Technology aims to enhance innovation-driven development and deepen industry-academia-research cooperation to lead breakthroughs in global marine pharmaceuticals and bioproducts [3]